Sana Biotechnology, Inc. (NASDAQ: SANA) is one of the 10 best healthcare penny stocks, according to analysts. The company's stock rose 12.1% on June 23 after it published six months of follow-up results from a human research sponsored by investigators on type 1 diabetes treatment.
Cell-grown cells for the development of gene therapy and cell therapy.
The focused treatment is UP421, which consists of islet cells covering genetically modified corpses using SANA's low-immunity (hip) technology to avoid immunodetection. An important finding is that the implanted cells were safe, resistant, survived, and continued to produce insulin in patients without the need for immunosuppressant drugs. This study did not identify safety issues, and hip-modified islet cells successfully circumvented the immune response (both allogeneic and autoimmune).
OLA Per-Ola Carlsson, Maryland, said the lead researcher, senior physician and professor at the clinic at Uppsala University Hospital, who said consistent results over the 4-week, 12-week, and now six months of follow-up suggest that functional treatment for type 1 diabetes without immunosuppression is possible.
Sana Biotechnology, Inc. (NASDAQ:SANA) is a biotechnology company. Develop engineered cell therapy to treat serious diseases, with the aim of repairing or replacing damaged cells. Its platforms include low immune cells, gene delivery, and in vivo cell engineering. SANA's pipeline targets conditions such as cancer, type 1 diabetes, and genetic disorders.
Although it recognizes SANA's potential as an investment, it believes certain AI stocks offer greater promotion potential and reduces the risk of a decline. If you're looking for a highly underrated AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report on the best short-term AI stocks.
Read next: Goldman Sachs Energy Stocks: 10 shares to buy and the best AI stock to buy, according to billionaire David Tepper.
Disclosure: None.
